Literature DB >> 10698204

Activin A-induced HepG2 liver cell apoptosis: involvement of activin receptors and smad proteins.

W Chen1, T K Woodruff, K E Mayo.   

Abstract

A balance between cell proliferation and apoptosis is important for regulating normal liver function. Proteins of the transforming growth factor-beta superfamily are known to be important mediators of apoptosis in the liver. In this study we demonstrate that activin A potently induces apoptotic cell death in a hepatoma cell line, HepG2 cells. To determine the roles of activin receptors and downstream signaling proteins in activin A-induced apoptosis in these cells, the activin signaling pathway was analyzed using the transcription of an activin-responsive reporter gene, p3TP-Lux, as an assay. Although individual activin receptors had little effect on transcriptional activity, coexpression of an activin type I receptor and a type II receptor significantly increased both basal and activin-induced transcriptional activation, with the combination ofreceptors IB and IIB being the most potent. Similarly, expression of individual Smad proteins had only a modest effect on reporter gene activity, but the combination of Smad2 and Smad4 strongly stimulated transcription. Activin signaling induced a rapid relocation of Smad2 to the nucleus, as determined using a green fluorescence protein-Smad2 fusion protein. In contrast, green fluorescence protein-Smad4 remained localized to the cytoplasm unless it was coexpressed with Smad2. In agreement with the transcriptional response assays, overexpression or suppression of activin signaling components in HepG2 cells altered apoptosis. Overexpression of receptors IB and IIB or Smad proteins 2 and 4 stimulated apoptosis, whereas dominant negative mutant forms of the activin type IIB receptor or Smad2 blocked activin-stimulated apoptosis. These studies suggest that signaling from the cell surface to the nucleus through Smad proteins is a required component of the activin A-induced cell death process in liver cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10698204     DOI: 10.1210/endo.141.3.7361

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  23 in total

Review 1.  Effects of physical activity upon the liver.

Authors:  Roy J Shephard; Nathan Johnson
Journal:  Eur J Appl Physiol       Date:  2014-11-04       Impact factor: 3.078

2.  ACVR1B (ALK4, activin receptor type 1B) gene mutations in pancreatic carcinoma.

Authors:  G H Su; R Bansal; K M Murphy; E Montgomery; C J Yeo; R H Hruban; S E Kern
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-13       Impact factor: 11.205

Review 3.  Activins and Inhibins: Roles in Development, Physiology, and Disease.

Authors:  Maria Namwanje; Chester W Brown
Journal:  Cold Spring Harb Perspect Biol       Date:  2016-07-01       Impact factor: 10.005

Review 4.  Expression and function of myostatin in obesity, diabetes, and exercise adaptation.

Authors:  David L Allen; Dustin S Hittel; Alexandra C McPherron
Journal:  Med Sci Sports Exerc       Date:  2011-10       Impact factor: 5.411

5.  Activin betaC and betaE genes are not essential for mouse liver growth, differentiation, and regeneration.

Authors:  A L Lau; T R Kumar; K Nishimori; J Bonadio; M M Matzuk
Journal:  Mol Cell Biol       Date:  2000-08       Impact factor: 4.272

6.  Gene expression profiling reveals Cyp26b1 to be an activin regulated gene involved in ovarian granulosa cell proliferation.

Authors:  Jingjing L Kipp; Ann Golebiowski; Guadalupe Rodriguez; Michael Demczuk; Signe M Kilen; Kelly E Mayo
Journal:  Endocrinology       Date:  2010-11-17       Impact factor: 4.736

7.  Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients.

Authors:  Andrea Pellagatti; Martin Jädersten; Ann-Mari Forsblom; Helen Cattan; Birger Christensson; Emma K Emanuelsson; Mats Merup; Lars Nilsson; Jan Samuelsson; Birgitta Sander; James S Wainscoat; Jacqueline Boultwood; Eva Hellström-Lindberg
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-18       Impact factor: 11.205

Review 8.  Activins and activin antagonists in hepatocellular carcinoma.

Authors:  Alev Deli; Emanuel Kreidl; Stefan Santifaller; Barbara Trotter; Katja Seir; Walter Berger; Rolf Schulte-Hermann; Chantal Rodgarkia-Dara; Michael Grusch
Journal:  World J Gastroenterol       Date:  2008-03-21       Impact factor: 5.742

9.  Farnesoid X receptor protects liver cells from apoptosis induced by serum deprivation in vitro and fasting in vivo.

Authors:  Yan-Dong Wang; Fan Yang; Wei-Dong Chen; Xiongfei Huang; Lily Lai; Barry M Forman; Wendong Huang
Journal:  Mol Endocrinol       Date:  2008-04-24

10.  Regulation of activin receptor-interacting protein 2 expression in mouse hepatoma Hepa1-6 cells and its relationship with collagen type IV.

Authors:  Hong-Jun Zhang; Gui-Xiang Tai; Jing Zhou; Di Ma; Zhong-Hui Liu
Journal:  World J Gastroenterol       Date:  2007-11-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.